Patents for A61P 35 - Antineoplastic agents (221,099)
03/2002
03/19/2002US6359002 Method for treating a patient with neoplasia by treatment with a platinum coordination complex
03/19/2002US6358987 For therapy and prophylaxis of rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, and tumour metastasis, invasion and growth
03/19/2002US6358985 Inhibitors of prenyl-protein transferase
03/19/2002US6358983 Heterocyclically substituted α-hydroxycarboxylic acid derivatives, method for producing the same and their use as endothelin receptor antagonists
03/19/2002US6358978 Substituted benzimidazoles
03/19/2002US6358976 For therapy and prophylaxis of cancer metastasis, diabetic retinopathy, neovascular glaucoma, thrombosis, restenosis, osteoporosis, or macular degeneration
03/19/2002US6358970 Integrin receptor antagonists
03/19/2002US6358968 N-substituted urea inhibitors of farnesyl-protein transferase
03/19/2002US6358962 6,7-Dimethoxyquinazolines and therapeutic use thereof
03/19/2002US6358961 Farnesyltransferase inhibiting quinazolinones
03/19/2002US6358957 Cancer therapy
03/19/2002US6358956 Inhibitors of prenyl-protein transferase
03/19/2002US6358954 PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
03/19/2002US6358953 Administering pterin metal complex as anticarcinogenic agents and viricides
03/19/2002US6358952 Combination of benzoquinazoline antifolates and protecting agents
03/19/2002US6358948 Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
03/19/2002US6358947 Tetracyclic progesterone receptor modulator compounds and methods
03/19/2002US6358940 Modified 2-Alkoxyestradiol derivatives with prolonged pharmacological activity
03/19/2002US6358937 Administering phosphatidic acid and lipid to treat drug abuse, addiction, or withdrawal and/or alcoholism
03/19/2002US6358936 Modified doxorubicin
03/19/2002US6358923 Preventing and diagnosing blood, genetic, and nervous system disorders associated with decreased genetic expression
03/19/2002US6358920 Nonapeptide anticarcinogenic and antimetastasis agents
03/19/2002US6358732 Nucleotide sequences preferential polypeptides for use in the treatment of defects in central nervous system
03/19/2002US6358710 Humanized antibodies that bind to the antigen bound by antibody NR-LU-13
03/19/2002US6358707 Polynucleotide sequences coding polypeptide associated with cellular secretion; for use in treatment of diabetes, stroke, atherosclerosis, restenosis, thrombosis, autoimmune disease, psoriasis, arthritis, crohn's, and inflammatory defects
03/19/2002US6358695 Determining compounds that activate or inhibit a g-protein receptor by exposing cells expressing the polypeptide on the surface with a test compound to allow binding and detect a signal in response to binding of agent to the polypeptide
03/19/2002US6358524 Target cell-specific non-viral vectors for inserting genes into cells, pharmaceutical compositions comprising such vectors and their use
03/19/2002US6358491 Somatostatin analogs
03/19/2002CA2236673C (-)cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate
03/19/2002CA2232488C Cancer chemoprotective food products
03/19/2002CA2179521C 2,4-disulphophenyl butylnitrone, its salts and their use as pharmaceuti cal spintraps
03/19/2002CA2173963C Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
03/19/2002CA2099779C Mixed specificity fusion proteins
03/19/2002CA2050331C Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
03/19/2002CA1341348C Human tumor necrosis factor
03/15/2002CA2357155A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
03/14/2002WO2002021138A2 The m30 gene family and the utilization thereof
03/14/2002WO2002021134A2 Methods of diagnosing breast cancer and screening for modulators
03/14/2002WO2002020846A2 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
03/14/2002WO2002020822A2 Biopanning and rapid analysis of selective interactive ligands (brasil)
03/14/2002WO2002020814A1 Self-rearranging dna vectors
03/14/2002WO2002020813A2 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
03/14/2002WO2002020807A1 L-methionine $g(g)-lyase with modified function
03/14/2002WO2002020788A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/14/2002WO2002020786A2 Kinase d interacting protein
03/14/2002WO2002020770A1 Method of screening antitumor agent by using interaction between arf protein and hk33 protein
03/14/2002WO2002020769A1 Human and mouse targeting peptides identified by phage display
03/14/2002WO2002020768A2 Caveolin peptides and their use as therapeutics
03/14/2002WO2002020767A2 G-csf analog compositions and methods
03/14/2002WO2002020766A2 G-csf analog compositions and methods
03/14/2002WO2002020762A2 Tnf receptor-like molecules and uses thereof
03/14/2002WO2002020759A2 A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
03/14/2002WO2002020743A1 A new polypeptide- human i kappa b kinase 15 and the polynucleotide encoding it
03/14/2002WO2002020736A2 Proteases
03/14/2002WO2002020724A2 Adenoviral targeting and manipulation of immune system response using targeting peptides
03/14/2002WO2002020723A2 Compositions and methods for targeting peptides in humans in vivo
03/14/2002WO2002020722A2 Methods and compositions for in vitro targeting
03/14/2002WO2002020621A1 Tetraphenylporphyrin derivatives and compositions comprising the same
03/14/2002WO2002020620A2 Monoclonal antibody against ovarian carcinoma
03/14/2002WO2002020619A2 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
03/14/2002WO2002020617A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma
03/14/2002WO2002020616A1 Hla-a2.1 binding peptides and their uses
03/14/2002WO2002020608A1 A new polypeptide- human lymph enhanced factor 42 and the polynucleotide encoding it
03/14/2002WO2002020607A1 A NEW POLYPEPTIDE-HUMAN BIPHENYL HYDROLASE-RELATED PROTEIN (Bph-rp)16.06 AND THE POLYNUCLEOTIDE ENCODING IT
03/14/2002WO2002020606A1 A new polypeptide- human hearing defect-related protein 38.39 and the polynucleotde encoding it
03/14/2002WO2002020605A1 A NEW POLYPEPTIDE-HUMAN CELL CYCLIN-E BINDING PROTEIN 1(Ceb1)113-70.07 AND THE POLYNUCLEOTIDE ENCODING IT
03/14/2002WO2002020604A1 A new polypeptide- human double-stranded rna binding protein 11 and the polynucleotide encoding it
03/14/2002WO2002020603A1 A new polypeptide- human tropomodulin 25.08 and the polynucleotide encoding it
03/14/2002WO2002020600A1 A new polypeptide- human zinc finger protein 10.45 and the polynucleotide encoding it
03/14/2002WO2002020599A1 A new polypeptide- human transcription regulation factor zfm1 isomer 19.47 and the polynucleotide encoding it
03/14/2002WO2002020598A1 Mucin
03/14/2002WO2002020590A1 A novel polypeptide-phosphoenolpyruvate-dependent sugar phosphotransferase 33 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020589A1 A novel polypeptide-the human retinoblastoma binding protein 19.91 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020588A1 A novel polypeptide-human transcriptional control factor zfm1 isomer 25.63 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020587A1 A novel polypeptide-human nadh dehydrogenase subunit i-12.43 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020586A1 A novel polypeptide-human large protein 10.23 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020581A1 A novel polypeptide-rna polymerase 11 related protein 11.33 and the polynucleotide encoding said polypeptide
03/14/2002WO2002020580A1 A novel polypeptide-human tnfr/ngfr protein 15 that contains cytochrome c structural domain and the polynucleotide encoding said polypeptide
03/14/2002WO2002020560A1 Novel human cancer/testis antigen and gene thereof
03/14/2002WO2002020536A1 Tetraphenylbacteriochlorin derivatives and compositions containing the same
03/14/2002WO2002020527A1 Soluble compounds for the inhibition of multidrug resistance and pharmaceutical compositions thereof
03/14/2002WO2002020526A2 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
03/14/2002WO2002020525A2 Protein tyrosine phosphatase inhibitor
03/14/2002WO2002020524A1 Oxindole derivatives
03/14/2002WO2002020513A1 Oxindole derivatives
03/14/2002WO2002020512A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
03/14/2002WO2002020500A2 Materials and methods to potentiate cancer treatment
03/14/2002WO2002020495A2 Inhibitors of glycogen synthase kinase 3
03/14/2002WO2002020486A2 Picolinic acid derivatives for the prevention and treatment of cancer in animals
03/14/2002WO2002020483A1 Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors
03/14/2002WO2002020479A1 Substituted oxindole derivatives as tyrosine kinase inhibitors
03/14/2002WO2002020478A1 N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer
03/14/2002WO2002020475A2 Inhibitors of serine protease activity of matriptase or mtsp1
03/14/2002WO2002020463A2 Fxr modulators
03/14/2002WO2002020112A1 Process for selectively extracting bioactive components
03/14/2002WO2002020092A1 Use of serum response factor (srf) modulator for treating srf related diseases
03/14/2002WO2002020060A1 Vp22 protein/nucleic acid aggregates, uses thereof
03/14/2002WO2002020053A1 Hla binding peptides and their uses
03/14/2002WO2002020039A2 Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
03/14/2002WO2002020035A1 Hla binding peptides and their uses